Innovent Biologics, Inc. (HKG:1801)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
102.40
+1.20 (1.19%)
Aug 21, 2026, 4:08 PM HKT

Innovent Biologics Stock Forecast

Stock Price Forecast

According to 28 analysts polled by S&P Global, Innovent Biologics stock has a consensus rating of "Strong Buy" and an average price target of $118.52. The average 1-year stock price forecast is 15.74% higher than the current stock price, while the lowest is $94.26 (-7.95%) and the highest is $140.72 (+37.42%).

Price Target: $118.52 (+15.74%)
Analyst Consensus: Strong Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$94.26$118.52$118.82$140.72
Change-7.95%+15.74%+16.04%+37.42%

Analyst Ratings

The average analyst rating for Innovent Biologics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart
RatingMar '26Apr '26May '26Jun '26Jul '26Aug '26
Strong Buy212222222121
Buy556666
Hold322111
Sell000000
Strong Sell000000
Total292930292828

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
DBS
DBS
Buy
Initiates
$144.00
BuyInitiates$144.00+40.62%Aug 18, 2026
Unknown Analyst
Daiwa
No rating
Daiwa
Buy
Maintains
$120.00
BuyMaintains$120.00+17.19%Aug 12, 2026
Unknown Analyst
BOCOM International Holdings Company
No rating
BOCOM International Holdings Company
Buy
Maintains
$105.00$118.00
BuyMaintains$105.00$118.00+15.23%Aug 7, 2026
J.P. Morgan
J.P. Morgan
Buy
Maintains
$117.00
BuyMaintains$117.00+14.26%Aug 6, 2026
Unknown Analyst
UOB Kay Hian
No rating
UOB Kay Hian
Buy
Maintains
$112.00
BuyMaintains$112.00+9.37%Jul 16, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
18.42B
from 13.04B
Increased by 41.27%
Revenue Next Year
22.43B
from 18.42B
Increased by 21.76%
EPS This Year
1.52
from 0.99
Increased by 53.23%
EPS Next Year
1.96
from 1.52
Increased by 29.00%
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
4.27B4.56B6.21B9.42B13.04B18.42B
Revenue Growth
11.08%6.71%36.21%51.82%38.42%41.27%
Gross Profit
3.05B3.17B4.40B7.16B10.00B16.00B
Gross Margin
71.32%69.67%70.89%76.03%76.66%86.85%
Operating Income
-2.70B-3.12B-1.56B-123.30M733.62M2.28B
Net Income
-2.73B-2.18B-1.03B-94.63M813.57M2.23B
EPS
----0.991.52
EPS Growth
-----53.23%
Forward PE
----42.6757.89
Free Cash Flow
-2.61B-2.48B-907.54M-17.42M3.23B3.31B
No. Analysts
-----28
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is CNY.

Revenue Forecast

Revenue202620272028
High24.2B
Avg18.4B
Low16.4B

Revenue Growth

Revenue Growth202620272028
High
85.8%
Avg
41.3%
Low
25.6%

EPS Forecast

EPS202620272028
High4.00
Avg1.52
Low0.63

EPS Growth

EPS Growth202620272028
High
304.2%
Avg
53.2%
Low
-36.3%